z-logo
open-access-imgOpen Access
Are the Newer Antidiabetic Agents Worth the Cost?
Author(s) -
Sudhakar Pemminati,
Richard M. Millis,
Ashwin Kamath,
Ashok Kudgi Shenoy,
Shivapraksh Gangachannaiah
Publication year - 2016
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2016/17683.7384
Subject(s) - medicine , exenatide , glimepiride , liraglutide , sitagliptin , metformin , type 2 diabetes mellitus , canagliflozin , saxagliptin , pioglitazone , pharmacology , dapagliflozin , linagliptin , intensive care medicine , diabetes mellitus , type 2 diabetes , endocrinology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom